How interest in a single cancer drug led to Ipsen's takeover of Epizyme
It’s been a tough year for biotech companies as a bear market tears through the sector. Epizyme began looking for ways to conserve cash back in January, months before it made the difficult decision to chop roughly 12% of its staff.
According to an inside account of its recent deal with Ipsen, the Cambridge, MA-based biotech and its consultants reached out to — and got rejected from — more than two dozen oncology companies about “possible strategic transactions” before the French pharma swooped in with an offer to buy the entire company for $247 million in cash.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.